Children's Mercy Kansas City, Kansas City, MO, 64108, USA.
University of Missouri-Kansas City, Kansas City, MO, 64110, USA.
Pediatr Res. 2023 Jul;94(1):200-205. doi: 10.1038/s41390-022-02374-4. Epub 2022 Nov 14.
A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children.
Prospective cohort study of immunocompromised participants, 5-21 years old, who received 2 prior doses of an mRNA COVID-19 vaccine. Humoral and CD4/CD8 T-cell responses were measured to SARS-CoV-2 spike antigens prior to receiving the 3rd vaccine dose and 3-4 weeks after the 3rd dose was given.
Of the 37 participants, approximately half were solid organ transplant recipients. The majority (86.5%) had a detectable humoral response after the 2nd and 3rd vaccine doses, with a significant increase in antibody levels after the 3rd dose. Positive T-cell responses increased from being present in 86.5% to 100% of the cohort after the 3rd dose.
Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This supports the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in this population.
Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This is the first prospective cohort study to analyze both the humoral and T-cell immune response to the 3rd COVID-19 primary vaccine dose in children who are immunocompromised. The results of this study support the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in the immunosuppressed pediatric population.
免疫功能低下人群对 2 剂 COVID-19 疫苗系列的反应不佳，促使人们建议接种第 3 剂基础疫苗。我们旨在确定免疫功能低下儿童接种第 3 剂 COVID-19 疫苗后的体液和细胞免疫反应。
前瞻性队列研究了 5-21 岁接受过 2 剂 mRNA COVID-19 疫苗的免疫功能低下参与者。在接种第 3 剂疫苗前和接种第 3 剂疫苗后 3-4 周，测量了针对 SARS-CoV-2 刺突抗原的体液和 CD4/CD8 T 细胞反应。
在 37 名参与者中，约一半为实体器官移植受者。大多数（86.5%）在第 2 剂和第 3 剂疫苗后出现可检测的体液反应，第 3 剂疫苗后抗体水平显著升高。第 3 剂疫苗后，T 细胞反应阳性的比例从 86.5%增加到 100%。
大多数免疫功能低下的儿童对 2 剂 COVID-19 疫苗系列产生体液和细胞免疫反应，在接种第 3 剂疫苗后显著增强。这支持了第 3 剂疫苗的有效性，以及在该人群中持续强调接种 COVID-19 疫苗的理由。
大多数免疫功能低下的儿童对 2 剂 COVID-19 疫苗系列产生体液和细胞免疫反应，在接种第 3 剂疫苗后显著增强。这是第一项前瞻性队列研究，分析了免疫功能低下儿童接种第 3 剂 COVID-19 基础疫苗后体液和 T 细胞免疫反应。这项研究的结果支持了第 3 剂疫苗的有效性，以及在免疫抑制的儿科人群中持续强调接种 COVID-19 疫苗的理由。
